Regulation of basal core promoter activity of human organic cation transporter 1 (OCT1/SLC22A1)

被引:16
|
作者
Kajiwara, Moto
Terada, Tomohiro
Asaka, Jun-ichi
Aoki, Masayo
Katsura, Toshiya
Ikai, Iwao [2 ]
Inui, Ken-ichi [1 ]
机构
[1] Kyoto Univ Hosp, Dept Pharm, Sakyo Ku, Fac Med, Kyoto 6068507, Japan
[2] Kyoto Univ, Dept Surg, Grad Sch Med, Kyoto, Japan
关键词
liver; E-box;
D O I
10.1152/ajpgi.90360.2008
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Human organic cation transporter 1 (OCT1/SLC22A1) plays important roles in the hepatic uptake of cationic drugs. The functional characteristics of this transporter have been well evaluated, but molecular information regarding transcriptional regulation is limited. In the present study, therefore, we examined the gene regulation of OCT1 gene focusing on basal core expression. An similar to 2.5-kb fragment of the OCT1 promoter region was isolated, and promoter activity was measured by luciferase assay in the human liver cell lines Huh7 and HepG2. Deletion analysis suggested that the region spanning -141/-69 was essential for the basal core transcriptional activity and that this region contained the sequence of a cognate E-box (CACGTG). The E-box is known to be bound by the basal transcription factors, upstream stimulating factors (USFs), and the functional involvements of USF1 and USF2 were confirmed by a transactivation effect, a mutational analysis of the E-box, and an electrophoretic mobility shift assay. The transactivation effect of USFs on the OCT1 promoter was further stimulated by hepatocyte nuclear factor 4 alpha, a liver-enriched transcription factor. There were no polymorphisms in the proximal promoter region (about 400 bp) of OCT1 gene (n = 109). These findings indicated that both USF1 and USF2 bind to an E-box sequence located in the OCT1 core promoter region and are required for the basal gene expression of this transporter.
引用
收藏
页码:G1211 / G1216
页数:6
相关论文
共 50 条
  • [1] Impact of Promoter Polymorphisms on the Transcriptional Regulation of the Organic Cation Transporter OCT1 (SLC22A1)
    Bokelmann, Kristin
    Brockmoeller, Juergen
    Tzvetkov, Mladen, V
    [J]. JOURNAL OF PERSONALIZED MEDICINE, 2018, 8 (04):
  • [2] Evaluation of organic cation transporter 1 (OCT1, SLC22A1) as transporter for sorafenib
    Neul, Claudia
    Baker, Sharyn D.
    Sparreboom, Alex
    Schaeffeler, Elke
    Laufer, Stefan
    Schwab, Matthias
    Nies, Anne T.
    [J]. CANCER RESEARCH, 2016, 76
  • [3] ORGANIC CATION TRANSPORTER 1 (OCT1; SLC22A1) MODULATES HEPATIC ENERGY METABOLISM
    Liang, X.
    Luo, Q.
    Yee, S.
    Chen, E. C.
    Chien, H. -C.
    King, S.
    Giacomini, K. M.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S8 - S8
  • [4] Discovery of Competitive and Noncompetitive Ligands of the Organic Cation Transporter 1 (OCT1; SLC22A1)
    Chen, Eugene C.
    Khuri, Natalia
    Liang, Xiaomin
    Stecula, Adrian
    Chien, Huan-Chieh
    Yee, Sook Wah
    Huang, Yong
    Sali, Andrej
    Giacomini, Kathleen M.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2017, 60 (07) : 2685 - 2696
  • [5] DNA methylation is associated with downregulation of the organic cation transporter OCT1 (SLC22A1) in human hepatocellular carcinoma
    Schaeffeler, Elke
    Hellerbrand, Claus
    Nies, Anne T.
    Winter, Stefan
    Kruck, Stephan
    Hofmann, Ute
    van der Kuip, Heiko
    Zanger, Ulrich M.
    Koepsell, Hermann
    Schwab, Matthias
    [J]. GENOME MEDICINE, 2011, 3
  • [6] DNA methylation is associated with downregulation of the organic cation transporter OCT1 (SLC22A1) in human hepatocellular carcinoma
    Elke Schaeffeler
    Claus Hellerbrand
    Anne T Nies
    Stefan Winter
    Stephan Kruck
    Ute Hofmann
    Heiko van der Kuip
    Ulrich M Zanger
    Hermann Koepsell
    Matthias Schwab
    [J]. Genome Medicine, 3
  • [7] INTERINDIVIDUAL VARIABILITY OF ORGANIC CATION TRANSPORTER OCT1 (SLC22A1) AND OCT3 (SLC22A3) EXPRESSION IN HUMAN LIVER
    Nies, Anne T.
    Schaeffeler, Elke
    Klein, Kathrin
    Zanger, Ulrich M.
    Kerb, Reinhold
    Koepsell, Hermann
    Keppler, Dietrich
    Schwab, Matthias
    [J]. DRUG METABOLISM REVIEWS, 2008, 40 : 153 - 154
  • [8] Sorafenib therapy for treatment of liver cancer is independent from organic cation transporter 1 (OCT1/SLC22A1)
    Chen, M.
    Neul, C.
    Schaeffeler, E.
    Frisch, F.
    Winter, S.
    Schwab, M.
    Koepsell, H.
    Hu, S.
    Laufer, S.
    Baker, S. D.
    Sparreboom, A.
    Nies, A. T.
    [J]. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2019, 392 : S17 - S18
  • [9] Interactions of antiretroviral drugs with the SLC22A1 (OCT1) drug transporter
    Moss, Darren M.
    Liptrott, Neill J.
    Siccardi, Marco
    Owen, Andrew
    [J]. FRONTIERS IN PHARMACOLOGY, 2015, 6
  • [10] STRUCTURAL REQUIREMENTS FOR DRUG INHIBITION OF THE HUMAN ORGANIC CATION TRANSPORT PROTEIN OCT1 (SLC22A1)
    Ahlin, Gustav
    Karlsson, Johan
    Pedersen, Jenny
    Gustavsson, Lena B. M.
    Larsson, Rolf
    Matsson, Par
    Norinder, Ulf
    Bergstrom, Christel A. S.
    Artursson, Per
    [J]. DRUG METABOLISM REVIEWS, 2008, 40 : 158 - 159